Banker Manish, Arora Parul, Banker Jwal, Shah Sandeep
Department of Reproductive Medicine, Nova IVF Fertility, Ahmedabad, Gujarat, India.
Department of Reproductive Medicine, IVI RMA, Madrid, Spain.
J Hum Reprod Sci. 2021 Jan-Mar;14(1):94-96. doi: 10.4103/jhrs.JHRS_69_20. Epub 2021 Mar 30.
Improvement in cancer treatments has allowed more women to plan a pregnancy once the disease is cured. The effects of chemotherapy on ovaries are well proven but those on the uterus, especially the endometrium and embryo implantation are still unknown. Usage of newer tyrosine kinase inhibitors such as nilotinib has revolutionized the management of leukemias. Although nilotinib has been reported to be safe in pregnancy, further studies are needed to evaluate its effect on the process of embryo implantation, especially in women undergoing fertilization. We report a case where successful pregnancy outcome was achieved after stoppage of nilotinib before embryo transfer in a woman who had previous four failed attempts while on nilotinib and no other obvious cause of implantation failure. Despite optimal endometrial thickness and receptivity, the pale appearance of endometrium on hysteroscopy was attributed to be a possible effect of nilotinib and prompted us to withhold it.
癌症治疗的进步使更多女性在疾病治愈后能够计划怀孕。化疗对卵巢的影响已得到充分证实,但对子宫,尤其是子宫内膜和胚胎着床的影响仍不清楚。使用新型酪氨酸激酶抑制剂如尼洛替尼彻底改变了白血病的治疗方式。尽管有报道称尼洛替尼在孕期是安全的,但仍需要进一步研究来评估其对胚胎着床过程的影响,尤其是对正在接受体外受精的女性。我们报告了一例病例,一名女性此前在服用尼洛替尼期间有四次胚胎移植失败且无其他明显着床失败原因,在胚胎移植前停用尼洛替尼后成功妊娠。尽管子宫内膜厚度和容受性最佳,但宫腔镜检查时子宫内膜的苍白外观被认为可能是尼洛替尼的影响,这促使我们停用该药。